Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

Proprotein convertase subtilisin kexin type 9 (PCSK9) lowers the abundance of surface low-density lipoprotein (LDL) receptor through an undefined mechanism. The structure of human PCSK9 shows the subtilisin-like catalytic site blocked by the prodomain in a noncovalent complex and inaccessible to exogenous ligands, and that the C-terminal domain has a novel fold. Biosensor studies show that PCSK9 binds the extracellular domain of LDL receptor with Kd = 170 nM at the neutral pH of plasma, but with a Kd as low as 1 nM at the acidic pH of endosomes. The D374Y gain-of-function mutant, associated with hypercholesterolemia and early-onset cardiovascular disease, binds the receptor 25 times more tightly than wild-type PCSK9 at neutral pH and remains exclusively in a high-affinity complex at the acidic pH. PCSK9 may diminish LDL receptors by a mechanism that requires direct binding but not necessarily receptor proteolysis.

[1]  T. Ranheim,et al.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. , 2006, Human molecular genetics.

[2]  N. Seidah,et al.  The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A , 2006, Journal of Biological Chemistry.

[3]  J. Breslow,et al.  Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia , 2005, Current opinion in lipidology.

[4]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[5]  B. Gabel,et al.  Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). , 1995, Biochemistry.

[6]  P. Petkov,et al.  Expression and localization of PCSK9 in rat hepatic cells. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[7]  Jonathan C. Cohen,et al.  Molecular biology of PCSK9: its role in LDL metabolism. , 2007, Trends in biochemical sciences.

[8]  R. Hammer,et al.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. , 2006, The Journal of clinical investigation.

[9]  S. Blacklow,et al.  Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. , 2006, Molecular cell.

[10]  Joseph L. Goldstein,et al.  Structure of the LDL Receptor Extracellular Domain at Endosomal pH , 2002, Science.

[11]  Jonathan C. Cohen,et al.  Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. , 2006, American journal of human genetics.

[12]  B. Ozenberger,et al.  Functional characterization of Narc 1, a novel proteinase related to proteinase K. , 2003, Archives of biochemistry and biophysics.

[13]  I. Lindberg,et al.  Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. , 2005, Journal of molecular biology.

[14]  R. Hammer,et al.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Prat,et al.  ZYMOGEN CLEAVAGE AND EFFECTS ON THE LOW DENSITY LIPOPROTEIN (LDL) RECEPTOR AND LDL CHOLESTEROL , 2004 .

[16]  M. Koschinsky,et al.  Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. , 1995, Biochemistry.

[17]  Robert Huber,et al.  The crystal structure of the proprotein processing proteinase furin explains its stringent specificity , 2003, Nature Structural Biology.

[18]  A. Prat,et al.  NARC-1/PCSK9 and Its Natural Mutants , 2004, Journal of Biological Chemistry.

[19]  P. Ljungdahl,et al.  Regulation of transcription factor latency by receptor-activated proteolysis. , 2006, Genes & development.

[20]  J. Orban,et al.  Solution structure of the pro-hormone convertase 1 pro-domain from Mus musculus. , 2002, Journal of molecular biology.

[21]  Robert Huber,et al.  1.2 A crystal structure of the serine carboxyl proteinase pro-kumamolisin; structure of an intact pro-subtilase. , 2004, Structure.

[22]  M. Inouye,et al.  The crystal structure of an autoprocessed Ser221Cys-subtilisin E-propeptide complex at 2.0 A resolution. , 1998, Journal of molecular biology.

[23]  Hyesung Jeon,et al.  Structure and physiologic function of the low-density lipoprotein receptor. , 2005, Annual review of biochemistry.

[24]  L. Bernier,et al.  Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[25]  A. Prat,et al.  The proprotein convertases and their implication in sterol and/or lipid metabolism , 2006, Biological chemistry.

[26]  M. Krempf,et al.  PCSK9: a promising therapeutic target for dyslipidemias? , 2006, Trends in Endocrinology & Metabolism.

[27]  T. Farag.  Familial hypercholesterolemia. , 1988, Journal of the Royal Society of Medicine.

[28]  Jonathan C. Cohen,et al.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. , 2006, American journal of human genetics.

[29]  Joseph L. Goldstein,et al.  The Cholesterol Quartet , 2001, Science.

[30]  Gregory A Petsko,et al.  2.4 A resolution crystal structure of the prototypical hormone-processing protease Kex2 in complex with an Ala-Lys-Arg boronic acid inhibitor. , 2003, Biochemistry.

[31]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[32]  J. Goldstein,et al.  Lowering LDL--Not Only How Low, But How Long? , 2006, Science.

[33]  A. Prat,et al.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Turk.  Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.

[35]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.